Show simple item record

dc.contributor.authorTurner, Rob
dc.contributor.authorWeaver, Sean
dc.contributor.authorCaserta, Francesco
dc.contributor.authorBrown, Marc B
dc.identifier.citationTurner , R , Weaver , S , Caserta , F & Brown , M B 2016 , ' A Novel Vehicle for Enhanced Drug Delivery Across the Human Nail for the Treatment of Onychomycosis ' International Journal of Pharmaceutical Compounding , vol 20 , no. 1 , pp. 71-80 .
dc.identifier.otherPURE: 10268485
dc.identifier.otherPURE UUID: fb360679-1399-4c3c-a9a4-8f92be6037f9
dc.identifier.otherPubMed: 27125057
dc.identifier.otherScopus: 84973410235
dc.descriptionTurner, R., Weaver, S., Caserta, F., Brown, M B., 'A Novel Vehicle for Enhanced Drug Delivery Across the Human Nail for the Treatment of Onyhomycosis', International Journal of Pharmaceutical Compounding, Vol 20(1): 71-80, Jan/Fab 2016. The version of record is available online at:
dc.description.abstractThe aim of this study was to use in vitro nail models to investigate the potential of a novel base formulation (Recura) containing either fluconazole or miconazole for the treatment of onychomycosis in comparison to two commercial comparators (Jublia and a Penlac generic). Initially, a modified Franz cell was used, where sections of human nail served as the barrier through which drug penetrated into an agar-filled chamber infected with dermatophytes. A second study was performed using a novel infected nail model where dermatophytes grew into human nail and adenosine triphosphate levels were used as biological marker for antimicrobial activity. The novel enhancing system Recura increased the permeation of both existing drugs through human nail sections mounted in a modified Franz cell. Furthermore, the infected nail model also confirmed that the system also enhanced the permeation through infected nail resulting in a decrease in adenosine triphosphate levels superior (P ≤ 0.05) to Penlac generic and equivalent (P > 0.05) to the commercial comparator Jublia. This study demonstrated that with the use of a novel permeation-enhancing formulation base, Recura enhances delivery of miconazole and fluconazole when applied ungually such that the efficacy was equivalent or superior to commercial comparators. Such a topically applied system has the possibility of overcoming the systemic side effects of antifungals when taken orally.en
dc.relation.ispartofInternational Journal of Pharmaceutical Compounding
dc.subjectAdenosine Triphosphate
dc.subjectAdministration, Topical
dc.subjectAntifungal Agents
dc.subjectChemistry, Pharmaceutical
dc.subjectDrug Delivery Systems
dc.titleA Novel Vehicle for Enhanced Drug Delivery Across the Human Nail for the Treatment of Onychomycosisen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionSkin and Nail Group
dc.contributor.institutionAirway Group
dc.contributor.institutionBioadhesive Drug Delivery Group
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
rioxxterms.typeJournal Article/Review

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record